Insider filing · SGMT
David Happel
President & CEO
profile →
Sagimet Biosciences Inc.
SGMT · Healthcare · 6 filings in 24 months
ticker →
David Happel sold $598K of Sagimet Biosciences (SGMT)
Executed Jul 21 2025, disclosed Jul 23 2025, 2 days later.
Value, as filed
$598K
65,478 sh × $9.13
Executed
Jul 21 2025
the trade date, as filed
Disclosed
Jul 23 2025
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
DHDavid Happel (President & CEO) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Sagimet Biosciences Inc. (SGMT). The largest single filing was $497K of SGMT (64,051 sh × $7.76, as filed), executed Jul 20.
The name
SGMTHealthcare · Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibit…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by David Happel in SGMT
SGMTSALE
Sagimet Biosciences Inc.
$497K64,051 sh × $7.76
Exec Jul 20
Filed Jul 22 · 4:05 PM ET